Form 4: Zoetis Executive Vice President Roxanne Lagano Reports Stock Sale Under 10b5-1 Plan

Roxanne Lagano, Executive Vice President of Zoetis Inc., reported the sale of 326 shares of common stock at $170 per share on March 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 10, 2025, Roxanne Lagano, an Executive Vice President at Zoetis Inc., sold 326 shares of common stock at a price of $170 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following the transaction, Ms. Lagano directly owns 15,781 shares of Zoetis Inc. common stock.
• She also indirectly owns 811.5728 shares through the Zoetis Inc. Savings Plan (401(k)) as of December 31, 2024.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing a stock sale by an executive under a pre-arranged trading plan. It doesn't convey strong positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies. The use of a 10b5-1 trading plan is a standard method for insiders to sell shares while avoiding accusations of insider trading.

Comparison to Industry Standards

• Executive stock sales are a common occurrence in publicly traded companies like Zoetis.
• Companies such as Eli Lilly, Merck, and Pfizer also have executives who regularly file Form 4s to report similar transactions.
• The use of 10b5-1 trading plans is a widely accepted practice among these companies to ensure compliance with insider trading regulations.

Stakeholder Impact

• The stock sale by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial performance.

Key Dates